Compare ELOG & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELOG | CMMB |
|---|---|---|
| Founded | 2006 | 2004 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1M | 10.8M |
| IPO Year | N/A | 2023 |
| Metric | ELOG | CMMB |
|---|---|---|
| Price | $0.85 | $1.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | 13.5K | ★ 217.7K |
| Earning Date | 07-17-2026 | 05-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $6.84 | $38.13 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.80 | $0.87 |
| 52 Week High | $3.07 | $3.86 |
| Indicator | ELOG | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 41.32 | 42.90 |
| Support Level | N/A | $1.51 |
| Resistance Level | $0.97 | $1.83 |
| Average True Range (ATR) | 0.06 | 0.27 |
| MACD | -0.00 | -0.05 |
| Stochastic Oscillator | 0.00 | 2.24 |
Eastern International Ltd is a holding company. The company operates through its subsidiary engaged in domestic and cross-border professional logistic services including project logistics and general logistics for company clients. Its project logistic services include Construction project logistics and special cargo logistics for large or precision equipment and General logistic services refer to the transportation, warehousing, loading and unloading, and distribution of ordinary products.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.